While Regulus was getting dinged this morning following some careful scrutiny of its latest hep C data, Achillion came out on top with new trial results which demonstrated that a combination of its NS5A inhibitor and Gilead's Sovaldi triggered a 6-week cure among all of the patients in a small study. And now researchers are using the data to set the stage to see if the results can be replicated even faster in a 4-week trial.
Investigators found that 50 mg of ACH-3102 and 400 mg of sofosbuvir did the trick for 12 out of 12 treatment-naive genotype 1 patients. CEO Milind Deshpande touted the results as the shortest duration, highest response results yet seen. He added: "Given the exceptional profile of ACH-3102, we will now be evaluating four- and six-week treatment durations that leverage all of our HCV assets including ACH-3102, ACH-3422, and sovaprevir."
Achillion is still looking to enter a fast-crowding marketplace. Competing drugs from Gilead and AbbVie have forced out earlier standard remedies with oral combos that are much easier to tolerate and much more likely to provide a lasting cure. The goal now is to find ways to do it quicker and with less expense, providing an opening for some of the companies still in the hunt.
Read more...
No comments:
Post a Comment